Ketamine and other glutamate receptor modulators for depression in adults

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 9, 2015, Pages

  Caddy, Caroline ^a   Amit, Ben H ^b,c   Mccloud, Tayla L ^a   Rendell, Jennifer M ^a   Furukawa, Toshi A ^d   Mcshane, Rupert ^e   Hawton, Keith ^e   Cipriani, Andrea ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

^b TEL AVIV UNIVERSITY   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMANTADINE; AMINO ACID RECEPTOR AFFECTING AGENT; ATOMOXETINE; CITALOPRAM; CYCLOSERINE; DEXTROMETHORPHAN; GLUTAMATE RECEPTOR MODULATOR; KETAMINE; LANICEMINE; MEMANTINE; MIDAZOLAM; ORG 26576; PLACEBO; QUINIDINE; QUINOLINIC ACID; RAPASTINEL; RILUZOLE; RISLENEMDAZ; SARCOSINE; THIOPENTAL; TRAMADOL; TRAXOPRODIL; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT;

ABDOMINAL DISCOMFORT; ABNORMAL BLOOD PRESSURE; ARTHRALGIA; ASTHENIA; BLURRED VISION; BODY WEIGHT GAIN; BODY WEIGHT LOSS; BONE PAIN; COGNITION; COMORBIDITY; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DREAMING; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; DYSTONIA; ELECTROCONVULSIVE THERAPY; EMOTIONAL DISORDER; EVIDENCE BASED MEDICINE; EYE IRRITATION; FATIGUE; GASTROINTESTINAL SYMPTOM; GENITAL SYSTEM DISEASE; GINGIVA DISEASE; HEADACHE; HEALTH CARE COST; HEART PALPITATION; HEART RATE VARIABILITY; HUMAN; INCREASED APPETITE; INFLUENZA; INSOMNIA; LIBIDO DISORDER; MAJOR DEPRESSION; MALAISE; MEMORY DISORDER; MICTURITION DISORDER; MIGRAINE; MUSCLE CRAMP; MYALGIA; NAUSEA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SORE THROAT; STOMACH DISCOMFORT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SWEATING; SYSTEMATIC REVIEW; TACHYCARDIA; TINNITUS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA; ADULT; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84954182078     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011612.pub2     Document Type: Review

References (232)

1. Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Psychiatry 2014;75:628-36.
2. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000;47:351-4.
3. Ghasemi M, Kazemi MH, YoosefiA, Ghasemi A, Paragomi P, Amini H, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Research 2013;215:355-61.
4. Heresco-Levy U, Javitt DC, Gelfin Y, Gorelik E, Bar M, Blanaru M, et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. Journal of Affective Disorders 2006;93:239-43.
5. Heresco-Levy U, Gelfin G, Bloch B, Levin R, Edelman S, Javitt DC, et al. A Randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression. International Journal of Neuropsychopharmacology 2013;16:501-6.
6. Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P, et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biological Psychiatry 2013;74(10):734-41.
7. Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs Add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012;37:1526-33. [: Riluzole]
8. Ibrahim L, Diazgranados N, Jolkovsky L, Brutsche N, Luckenbaugh DA, Herring J, et al. A randomized, placebo-controlled crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychopharmacology 2012;32:551-7.
9. Jarventausta K, Chrapek W, Kampman O, Tuohimaa K, Bjorkqvist M, Hakkinen H, et al. Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: A randomized pilot study. Journal of ECT 2013;29:158-61.
10. Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological Psychiatry 2014;76(12):970-6.
11. Loo CK, Katalinic N, Garfield JB, Sainsbury K, Hadzi-Pavlovic D, Mac-Pherson R. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. Journal of Affective Disorders 2012;142:233-40.
12. Michelson D, Adler LA, Amsterdam JD, Dunner DL, Nierenberg AA, Reimherr FW, et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2007;68:582-7.
13. Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015;40(5):1084-90.
14. Murrough JW, Iosifescu DV, Chang LC, Al JRK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. American Journal of Psychiatry 2013;170:1134-42.
15. Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, et al. Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression. Depression and Anxiety 2014;31:335-43.
16. Nations KR, Dogterom P, Bursi R, Schipper J, Greenwald S, Zraket D, et al. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: An exploratory, randomized, double-blind, placebo-controlled trial. Journal of psychopharmacology 2012;26:1525-39.
17. Nations KR, Dogterom P, Bursi R, Schipper J, Greenwald S, Zraket D, et al. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: An exploratory, randomized, double-blind, placebo-controlled trial. Journal of psychopharmacology 2012;26:1525-39.
18. Omranifard V, Shirzadi E, Samandari S, Afshar H, Maracy MR. Memantine add on to citalopram in elderly patients with depression: A double-blind placebo-controlled study. Journal of Research in Medical Sciences 2014;19:525-30.
19. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder. Journal of Clinical Psychopharmacology 2008;28:631-7.
20. Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Molecular Psychiatry 2014;19(9):978-85.
21. Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Molecular Psychiatry 2014;19(9):978-85.
22. Smith EG, Deligiannidis KM, Ulbricht CM, Landolin CS, Patel JK, Rothschild AJ. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry Diseases of the Nervous System 2013;74:966-73.
23. Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinology Letters 2013;34(4):287-93.
24. YoosefiA, Sepehri AS, Kargar M, Akhondzadeh S, Sadeghi M, Rafei A, et al. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: A randomized, double-blind study. Journal of ECT 2014;30:15-21.
25. Zarate C, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006;63:856-64.
26. Zarate C, Singh JB, Quiroz JA, De JG, DenicoffKK, Luckenbaugh DA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. American Journal of Psychiatry 2006;163:153-5.
27. Zarate C, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, et al. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biological Psychiatry 2013;74:257-64.
28. Aan Het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry 2010;67:139-45.
29. Abdallah CG, Fasula M, Kelmendi B, Sanacora G, OstroffR. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. Journal of ECT 2012;28:157-61.
30. Antic Srdjan D, Zhou Wen-Liang, Moore Anna R, Short Shaina M, Ikonomu Katerina D. The decade of the dendritic NMDA spike. Journal of Neuroscience Research 2010;88:2991-3001.
31. Barzman DH, DelBello MP, Kowatch RA, Gernert B, Fleck DE, Pathak S, et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: A retrospective chart review. Journal of Child and Adolescent Psychopharmacology 2005;14:593-600.
32. BondolfiG, Lissner C, Kosel M, Eap CB, Baumann P. Fluoxetine augmentation in citalopram non-responders: Pharmacokinetic and clinical consequences. International Journal of Neuropsychopharmacology 2000;3:55-60.
33. Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, Grillon C, et al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biological Psychiatry 2012;72:555-61.
34. DeBattista C, Solvason HB, Breen JA, Schatzberg AF. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. Journal of Clinical Psychopharmacology 2000;20(2):274-5.
35. Denk MC, Rewerts C, Holsboer F, Erhardt-Lehmann A, Turck CW. Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. The American Journal of Psychiatry 2011;168(7):751-2.
36. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 2013;38(5):743-52.
37. Fabbri C, Drago A, Serretti A. Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. European Neuropsychopharmacology 2013;23:612-21.
38. Ferguson JM, Shrivastava RK, Stahl SM, Hartford JT, Borian F, Ieni J, et al. Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. Journal of Clinical Psychiatry 2001;62:24-9.
39. Furey M, Drevets W, Khanna A, Zarate C. Differences in response to implicit emotional faces in anterior cingulate cortex predict antidepressant response to scopolamine in major depressive disorder abstract. Biological Psychiatry. Abstracts of the 67th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry; 2012 May 3-5; Philadelphia, (PA). 2012; Vol. 71.
40. Galvez V, O'Keefe E, Cotiga L, Leyden J, Harper S, Glue P, et al. Long-lasting effects of a single subcutaneous dose of Ketamine for treating melancholic depression: A case report. Biological Psychiatry 2014;76:e1-2.
41. Garriock HA, Tanowitz M, Kraft JB, Dang VC, Peters EJ, Jenkins GD, et al. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. American Journal of Psychiatry 2010;167:565-73.
42. Giese M, Beck J, Brand S, Muheim F, Hemmeter U, Hatzinger M, et al. Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation. Journal of Psychiatric Research 2014;59:1-7.
43. Gosek P, Chojnacka M, Bienkowski P, Swiecicki L. Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy. Psychiatria Polska 2014;48(1):49-58.
44. Hillemacher T, Bleich S, Demling J, Kornhuber J. Ketamine for the treatment of depression: what about the addictive potential?. Australian and New Zealand Journal of Psychiatry 2007;41:772-3.
45. Huey ED, Dustin IH, Overman GP, Mirza N, Sunderland T. Development of subtle psychotic symptoms with memantine: A case report 4 [letter]. Journal of Clinical Psychiatry 2005;66:658-9.
46. Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG, et al. Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. Progress in Neuro-psychopharmacology and Biological Psychiatry 2011;35:1155-9.
47. Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. Journal of Palliative Medicine 2010;13:903-8.
48. Janssen Research Development L L C. An Exploratory, Blinded, Randomized, Placebo-controlled Study in Subjects With Depressive Disorder to Investigate the Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced (Partial) Symptoms Response. http://clinicaltrials.gov/show/NCT01809340 2013.
49. Jeon H J, Woo J M, Lee S H, Kim E J, Chung S H, Ha J H, et al. Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: Tianeptine versus escitalopram. European neuropsychopharmacology 2013;Conference: 26th European College of Neuropsychopharmacology, ECNP Congress Barcelona Spain. Conference Start: 20131005 Conference End: 20131009. Conference Publication::S320-1.
50. Kaddurah-Daouk R. Pharmacometabolomic analysis of depression and treatment outcomes abstract. Biological psychiatry [abstracts of the 68th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry, SOBP; 2013 May 16-18; San Francisco, CA United States]. 2013:107S-8S.
51. Keating G M. Loxapine inhalation powder: A review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS drugs 2013;27:479-89.
52. Kollmar Rainer, Markovic Katrin, Thurauf Norbert, Schmitt Hubert, Kornhuber Johannes. Ketamine followed by memantine for the treatment of major depression. Australian and New Zealand journal of psychiatry 2008;42:170.
53. Kratochvil C J, Newcorn J H, Arnold L E, Duesenberg D, Emslie G J, Quintana H, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. Journal of the American Academy of Child and Adolescent Psychiatry 2005;44:915-24.
54. Larkin G L, Beautrais A L. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. International journal of neuropsychopharmacology 2011;14:1127-31.
55. Liebrenz M, Stohler R, Borgeat A. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World journal of biological psychiatry 2009;10:640-3.
56. Martin D M, Katalinic N, Ingram A, Schweitzer I, Smith D J, Hadzi-Pavlovic D, et al. A new early cognitive screening measure to detect cognitive side-effects of electroconvulsive therapy?. Journal of psychiatric research 2013;47:1967-74.
57. Muhonen L H, Lahti J, Alho H, Lonnqvist J, Haukka J, Saarikoski S T. Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence NCT00368862. Psychiatry research 2011;186:53-7.
58. Muniz Paulo S, Nardi Antonio E. Refractory pain-depression syndrome treated with tianeptine: A case report. Australian and New Zealand journal of psychiatry 2004;38:176.
59. NCT00826111. The effects of eszopiclone and lexapro on prefrontal glutamate and GABA in depression with co-morbid anxiety and insomnia: a proton MRS Study. https://clinicaltrials.gov/ct2/show/NCT00826111 (August 28th 2015).
60. O'Reardon J P, Fontecha J F, Cristancho M A, Newman S. Unexpected reduction in migraine and psychogenic headaches following rTMS treatment for major depression: a report of two cases. CNS spectrums 2007;12:921-5.
61. Omdal Roald, Brokstad K, Waterloo K, Koldingsnes W, Jonsson R, Mellgren S I. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. European journal of neurology 2005;12:392-8.
62. Paddock S, Laje G, Charney D, Rush A J, Wilson A F, Sorant A J M, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. American journal of psychiatry 2007;164:1181-8.
63. Pittenger Christopher, Naungayan Christine, Kendell Steven F, Coric Vladimir, Malison Robert, Krystal John H, et al. Visual Hallucinations from the Addition of Riluzole to Memantine and Bupropion. Journal of clinical psychopharmacology 2006;26:218-20.
64. Robson Matthew J. The involvement of sigma receptor modulation in the antidepressant effects of ketamine and the neurotoxic actions of methamphetamine. Dissertation abstracts international: section b: the sciences and engineering dissertation abstracts international 2014;75:No-Specified.
65. Sadavoy J, Bain J. An open-label, pilot study evaluating the safety and antidepressant effects of rellidep in major depressive disorder. Journal of clinical psychopharmacology 2014;34:230-3.
66. Srivastava S, Wang P W, Hill S J, Childers M E, Keller K L, Ketter T A. Pilot study of the efficacy of double-blind, placebo-controlled one-week olanzapine stabilization therapy in heterogeneous symptomatic bipolar disorder patients. Journal of psychiatric research 2012;46:920-6.
67. Starte J M, Fung A T, Kerdraon Y A. Ketamine-associated corneal edema. Cornea 2012;31:572-4.
68. Szymkowicz Sarah M, Finnegan Nora, Dale Roman M. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. Journal of affective disorders 2013;147:416-20.
69. Tsutsui Ko, Kanbayashi Takashi, Tanaka Keiko, Boku Shuken, Ito Wakako, Tokunaga Jun, et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC psychiatry 2012;12:37.
70. Wein S, Spruyt O, Chapman R. Ketamine as a possible cause of delirium. Journal of pharmacy practice and research 2002;32:212-4.
71. Weintraub D, Mavandadi S, Horn S, Siderowf A, Duda J, Stern M. Atomoxetine for the treatment of depression in Parkinson's disease: a randomised, double-blind, placebo-controlled study meeting abstract. American Journal of Geriatric Psychiatry [abstracts from the 14th Annual Meeting of the American Association of Geriatric Psychiatry (AAGP), Honolulu, Hawai'i, 5-8 March 2009]. 2009; Vol. 17.
72. Wernicke J F. Safety and side effect profile of fluoxetine. Expert opinion on drug safety 2004;3:495-504.
73. Yang L P H, Scott L J. Escitalopram: In the treatment of major depressive disorder in adolescent patients. Pediatric Drugs 2010;12:155-62.
74. Zourkova A, Hadasova E, Pilarova L, Ravcukova B, Kasparek T. Clinical Impact of CYP2D6 Activity in Long-term Paroxetine Treatment. New developments in anxiety disorder research. New York: Nova Science Publishers, 2006:177-98.
75. Calvisi V, Ansseau M. Mental confusion due to the administration of tramadol in a patient treated with MAOI [French]. Revue Medicale de Liege 1999;54(12):912-3.
76. Chan HN, Alonzo A, Martin DM, Mitchell PB, Sachdev P, Loo CK. Augmenting transcranial direct current stimulation with (D)-cycloserine for depression: a pilot study. Journal of ECT 2013;29:196-200.
77. Clark P. Treatment-refractory depression: A case of successful treatment with intranasal ketamine 10%. Annals of Clinical Psychiatry 2014;26:145.
78. Daly E, Kent J, Drevets W, Kezic I, Lane R, Lim P, et al. Efficacy and safety of a novel mGlu2 receptor positive allosteric modulator as an adjunctive treatment in anxious depression. European Neuropsychopharmacology 2014;24(Suppl 2):S453-S454.
79. Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. Annals of Pharmacotherapy 2004;38:411-3.
80. IRCT201104092266N2. Comparison of the effect of electroconvulsive therapy and intravenous infusion of ketamine on control and relapse of depressive symptoms in depressive cases who are candidates of electro convulsive therapy. http://www.irct.ir/searchresult.php?id=2266&number=2 (August 28th 2015).
81. ISRCTN14689382. Ketamine augmentation of ECT to improve outcomes in depression. http://isrctn.org/ISRCTN14689382 (August 28th 2015).
82. ISRCTN87057460. Effectiveness of the dual serotonin norepinephrine reuptake inhibitor venlafaxine in depressed patients. http://www.isrctn.com/ISRCTN87057460 (August 28th 2015).
83. McInnes EJ, James NM. A comparison of ketamine and methohexital in electroconvulsive therapy. Medical Journal of Australia 1972;1:1031-2.
84. NCT01046630. A Phase I, multi-centre, double-blind, placebo-controlled parallel group study to assess the pharmacoMRI effects of AZD6765 in male and female subjects fulfilling the criteria for major depressive disorder. http://clinicaltrials.gov/show/NCT01046630 (August 28th 2015).
85. NCT01306760. The use of ketamine as an anaesthetic during electroconvulsive therapy (ECT) for depression: does it improve treatment outcome?. http://clinicaltrials.gov/show/NCT01306760 (August 28th 2015).
86. NCT01482221. A multicenter, randomized, double-blind, parallel group, placebo-controlled, phase IIb efficacy and safety study of adjunctive AZD6765 in patients with major depressive disorder (MDD) and a history of inadequate response to antidepressants study D6702C00031. http://clinicaltrials.gov/show/NCT01482221 (August 28th 2015).
87. NCT01627782. A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of ketamine in subjects with treatment-resistant depression. http://clinicaltrials.gov/show/NCT01627782 (August 28th 2015).
88. Popp D, Burch R, Williams JBW, Price LM, Detke MJ. A phase ii randomized, double-blind, placebo-controlled trial of GLYX-13 for the rapid treatment of major depressive disorder using central ratings [abstract]. European Psychiatry 2013;28(Suppl 1):1.
89. Rasmussen KG, Kung S, Lapid MI, Oesterle TS, Geske JR, Nuttall GA, et al. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Research 2014;215:362-5.
90. Ruiz-Chow A, Ramirez-Bermudez J, Alviso-de la Serna L, Rios C. Amantadine: A treatment for major depressive disorder conference [abstract]. European Neuropsychopharmacology. Proceedings of the 23rd European College of Neuropsychopharmacology (ECNP) Congress; 2010 Aug 28-Sept 01; Amsterdam. 2010; Vol. 20:S352.
91. Singh J, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, et al. Efficacy and safety of intravenous esketamine in patients with treatment-resistant depression: A double-blind, double-randomization, placebo controlled phase 2a study abstract. Neuropsychopharmacology. Abstracts of the 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8-12; Hollywood, FL. 2013; Vol. 38:S369-70.
92. Singh J, Fedgchin M, Daly E, De Boer P, Cooper K, Lim P, et al. A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of intravenous ketamine in patients with treatment-resistant depression abstract. Biological Psychiatry. Abstracts of the 69th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry, SOBP; 2014 May 8-10; New York, NY. 2014:44S.
93. EUCTR2011-001520-37-SE. Ketamine as an alternative to electroconvulsive therapy for treatment of major depressive disorder. https://www.clinicaltrialsregister.eu/ctr-search/search?query=Vestibular+Disorders (August 28th 2015).
94. EUCTR2011-005476-41-GB. Ketamine augmentation of ECT to improve outcomes in depression - Ketamine-ECT study. https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005476-41/GB (August 28th 2015).
95. IRCT201307181556N54. Riluzole as adjuvant therapy in the treatment of moderate to severe major depression: A double - blind placebo-controlled trial. http://www.irct.ir/searchresult.php?keyword=&id=1556&number=54&prt=5237&total=10&m=1 (August 28th 2015).
96. NCT00988663. Memantine augmentation of electroconvulsive therapy in patients with major depression. http://clinicaltrials.gov/show/NCT00988663 (August 28th 2015).
97. NCT01179009. A safe ketamine-based therapy for treatment resistant depression. http://clinicaltrials.gov/show/NCT01179009 (August 28th 2015).
98. NCT01204918. Efficacy and tolerability of riluzole in treatment resistant depression. http://clinicaltrials.gov/show/NCT01204918 (August 28th 2015).
99. NCT01260649. N-methyl-D-aspartate antagonist (ketamine) augmentation of electroconvulsive treatment for severe major depression. http://clinicaltrials.gov/show/NCT01260649 (August 28th 2015).
100. NCT01441505. A study of ketamine as an antidepressant. http://clinicaltrials.gov/show/NCT01441505 (August 28th 2015).
101. NCT01557712. Estimate the efficiency of the association of an injection of ketamine and the venlafaxine in the severe major depressive disorder for six weeks (KETADEP). http://clinicaltrials.gov/show/NCT01557712 (August 28th 2015).
102. NCT01558063. The antidepressant action of ketamine: brain chemistry. http://clinicaltrials.gov/show/NCT01558063 (August 28th 2015).
103. NCT01613820. Combination of anticholinergic and glutamatergic effects in treatment-resistant major depressive disorder. A pilot study. http://clinicaltrials.gov/show/NCT01613820 (August 28th 2015).
104. NCT01667926. Randomized, double-blind ketamine augmentation in chronically suicidal, treatment-resistant major depression. http://clinicaltrials.gov/show/NCT01667926 (August 28th 2015).
105. NCT01684163. Phase 2, double-blind, placebo controlled, randomized withdrawal, parallel efficacy and safety study of GLYX-13 in subjects with inadequate/partial response to antidepressants during the current episode of major depressive disorder. http://clinicaltrials.gov/show/NCT01684163 (August 28th 2015).
106. NCT01700829. Ketamine vs. midazolam: testing rapid relief of suicide risk in depression. http://clinicaltrials.gov/show/NCT01700829 (August 28th 2015).
107. NCT01703039. Riluzole augmentation pilot in depression (RAPID) trial. http://clinicaltrials.gov/show/NCT01703039 (August 28th 2015).
108. NCT01868802. Ketamine for treatment-resistant depression: a multicentric clinical trial in Mexican population. http://clinicaltrials.gov/show/NCT01868802 (August 28th 2015).
109. NCT01880593. Ketamine plus lithium as a novel pharmacotherapeutic strategy in treatment-resistant depression. http://clinicaltrials.gov/show/NCT01880593 (August 28th 2015).
110. NCT01881763. Comparing therapeutic efficacy and cognitive side effects of electroconvulsive therapy (ECT) using ketamine versus methohexital anesthesia. http://clinicaltrials.gov/show/NCT01881763 (August 28th 2015).
111. NCT01882829. Targeting the NMDA glutamate receptor as novel antidepressant strategy: a pilot clinical trial of nuedexta in treatment-resistant major depression. http://clinicaltrials.gov/show/NCT01882829 (August 28th 2015).
112. NCT01887990. Treatment of suicidal ideation with intravenous ketamine infusion. http://clinicaltrials.gov/show/NCT01887990 (August 28th 2015).
113. NCT01902004. Treatment of geriatric depression with mild cognitive impairment: a double-blind placebo-controlled trial of namenda (memantine) augmentation of lexapro (escitalopram) in depressed patients at least 60 years of age. http://clinicaltrials.gov/show/NCT01902004 (August 28th 2015).
114. NCT01920555. Double-blind, placebo-controlled trial of ketamine therapy in treatment-resistant depression (TRD). http://clinicaltrials.gov/show/NCT01920555 (August 28th 2015).
115. NCT01935115. A prospective randomized double blinded control trial using ketamine or propofol anesthesia for electroconvulsive therapy: improving treatment-resistant depression. http://clinicaltrials.gov/show/NCT01935115 (August 28th 2015).
116. NCT01944293. Ketamine vs. midazolam in bipolar depression. http://clinicaltrials.gov/show/NCT01944293 (August 28th 2015).
117. NCT01945047. Phase 2 optimization of the antidepressant action of ketamine in treatment-resistant depression and investigations on its mechanism of action. http://clinicaltrials.gov/show/NCT01945047 (August 28th 2015).
118. NCT01957410. An open-label and double-blind study to investigate evoked potentials as markers of ketamine-induced cortical plasticity in subjects with major depressive disorder. http://clinicaltrials.gov/show/NCT01957410 (August 28th 2015).
119. NCT02012335. Ketamine use in electroconvulsive therapy: clinical, cognitives and neurotrophic outcomes. http://clinicaltrials.gov/show/NCT02012335 (August 28th 2015).
120. NCT02014363. Double blind, non-inferiority study to evaluate the antidepressant activity of ETS6103 compared with amitriptyline in the treatment of major depressive disorder (MDD) in patients who have an unsatisfactory response to selective serotonin re-uptake Inhibitors (SSRIs). http://clinicaltrials.gov/show/NCT02014363 (August 28th 2015).
121. NCT02037503. Effect of oral ketamine treatment on suicidal ideation and drug resistant major depression, a clinical and fMRI study. http://clinicaltrials.gov/show/NCT02037503 (August 28th 2015).
122. NCT02067793. Phase 2, randomized, double-blind, multiple-dose level, placebo controlled, single intravenous dose, parallel efficacy and safety study of NRX-1074 in subjects with major depressive disorder. http://clinicaltrials.gov/show/NCT02067793 (August 28th 2015).
123. NCT02106325. A randomized, double-blinded controlled trial of an N-methyl D-aspartate antagonist as a rapidly-acting antidepressant in depressed emergency department patients. http://clinicaltrials.gov/show/NCT02106325 (August 28th 2015).
124. NCT02139540. Nitrous oxide as treatment for major depression - a pilot study. http://clinicaltrials.gov/show/NCT02139540 (August 28th 2015).
125. NCT02153502. A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deuterium modified dextromethorphan hydrobromide/quinidine sulfate) as an adjunctive therapy in patients with Major depressive disorder with an inadequate response to antidepressant treatment. http://clinicaltrials.gov/show/NCT02153502 (August 28th 2015).
126. NCT02267980. Effect of the addition of ketamine to sevoflurane anesthesia in electroconvulsive therapy. http://clinicaltrials.gov/show/NCT02267980 (August 28th 2015).
127. NCT02295787. Intranasal ketamine for late-life depression and suicidal ideation. http://clinicaltrials.gov/show/NCT02295787 (August 28th 2015).
128. NCT02299440. Evaluation of the effects of ketamine in the acute phase of suicidal ideation: a multicenter randomized double-blind trial. http://clinicaltrials.gov/show/NCT02299440 (August 28th 2015).
129. NCT02305394. Effect of subanesthetic dose of ketamine combined with propofol on cognitive function in depressive patients undergoing electroconvulsive therapy - a randomized control double-blind clinical trial. http://clinicaltrials.gov/show/NCT02305394 (August 28th 2015).
130. NTR3753. ECT and Memantine. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=3753 (August 28th 2015).
131. Quiroz JA, Tamburri P, Deptula D, Banken L, Beyer U, Fontoura P, et al. The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomised, double-blind, placebo-controlled study [abstract]. European Neuropsychopharmacology. 2014; Vol. Proceedings of the 27th European College of Neuropsychopharmacology; 2014 Oct 18-21; Berlin:S468.
132. Singh J, Fedgchin M, Daly E, De Boer P, Cooper K, Lim P, et al. Onset of efficacy of ketamine in treatment resistant depression: A double-blind, randomised, placebo-controlled, dose frequency [abstract]. European Neuropsychopharmacology 2014;Prfoceedings of the 27th European College of Neuropsychopharmacology, ECNP Congress; 2014 Oct 18-21; Berlin:S387-8.
133. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here?. Biol Psychiatry 2012;72:537-47.
134. Abel KM, Allin MP, Kucharska-Pietura K, David A, Andrew C, Williams S, et al. Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport 2003;14:387-91.
135. Abrams R, Morrison JE, Villasenor A, Hencmann D, Da Fonseca M, Mueller W. Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesth Prog 1993;40:63-6.
136. Akinfiresoye L, Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology (Berl) 2013;230:291-8.
137. Alt A, Witkin JM, Bleakman D. AMPA receptor potentiators as novel antidepressants. Curr Pharm Des 2005;11:1511-27.
138. Altamura C, Maes M, Dai J, Meltzer HY. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol 1995;5 Suppl:71-5.
139. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
140. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, D.C: American Psychiatric Association, 1980.
141. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, D.C: American Psychiatric Association, 1987.
142. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, D.C: American Psychiatric Association, 1994.
143. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
144. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington (VA): American Psychiatric Association, 2013.
145. Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI:]
146. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490.
147. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011;475:91-5.
148. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?. Journal of Clinical Psychiatry 2006;67(9):1428-34.
149. Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 2011;16:1068-70.
150. Birkenhager TK, Moleman P, Nolen WA. Benzodiazepines for depression? A review of the literature. Int Clin Psychopharmacol 1995;10:181-95.
151. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomized controlled trials: quantifying the risks of false-positives and false-negatives. Health Technology Assessment 2001;5(33):1-56.
152. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology 2004;57(3):229-36.
153. Browne CA, Lucki I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 2013;4:161.
154. Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Therapeutic Advances in Psychopharmacology 2014;4(2):75-99.
155. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373(9665):746-58.
156. Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI:]
157. Cohen MG, Chan SL, Bhargava HN, Trevor AJ. Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochem Pharmacol 1974;23:1647-52.
158. Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967;113:1237-64.
159. Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta-analysis. Human Psychopharmacology 2015;30:152-163.
160. De Leo D, Too LS. Suicide and depression. In: Okpaku, SO editor(s). Essentials of Global Mental Health. Cambridge: Cambridge University Press, 2014:367-73.
161. Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem A, et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry 2011;168:727-34.
162. Donohue JM, Pincus HA. Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment. Pharmacoeconomics 2007;25:7-24.
163. Dozois D J A, Dobson K S. Depression. In: Antony M M, Barlow D H editor(s). Handbook of Assessment and Treatment Planning for Psychological Disorders. New York: Guilford Press, 2004:259-299.
164. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
165. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving crossover trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
166. Feighner JP, Robins E, Guze SB, WoodruffRA, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 1972;26(1):57-63.
167. Furukawa TA, Guyatt GH, Griffith LE. An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31(1):72-6.
168. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology 2005;20(1):49-52.
169. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10.
170. Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 2007;297(5):468-70.
171. Furukawa TA, Akechi T, Azuma H, Okuyama T, Higuchi T. Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression. Journal of Clinical Psychopharmacology 2007;27(5):531-4.
172. McMaster University (developed by Evidence Prime, Inc.). GRADEproGDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org]. Hamilton: McMaster University (developed by Evidence Prime, Inc.), 2015.
173. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): U.S. Department of Health and Human Services, 1976.
174. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomised trials. BMJ 1998;316(7132):690-3.
175. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
176. Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians?. World Psychiatry 2010;9:155-61.
177. Hasler G, van der Veen JW, Grillon C, Drevets WC, Shen J. Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy. Am J Psychiatry 2010;167(10):1226-31.
178. Hawton K, van Heeringen K. Suicide. Lancet 2009;373:1372-81.
179. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
180. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration.
181. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
182. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane collaboration.
183. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000;61 Suppl 6:4-6.
184. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007;27:11496-500.
185. Kavalali ET, Monteggia LM. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry 2012;169:1150-6.
186. Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets 2005;9:153-68.
187. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105.
188. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602.
189. Knox JW, Bovill JG, Clarke RS, Dundee JW. Clinical studies of induction agents. XXXVI: Ketamine. Br J Anaesth 1970;42:875-85.
190. Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011;224:107-11.
191. Layer RT, Popik P, Olds T, Skolnick P. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol Biochem Behav 1995;52:621-7.
192. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959-64.
193. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008;63:349-52.
194. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, et al. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 2012;26:189-204.
195. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine 2015;45:693-704.
196. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17:2921-7.
197. Moher D, Liberati A, TetzlaffJ, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. BMJ 2009;339:2535.
198. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9.
199. Morita T, Hitomi S, Saito S, Fujita T, Uchihashi Y, Kuribara H. Repeated ketamine administration produces up-regulation of muscarinic acetylcholine receptors in the forebrain, and reduces behavioral sensitivity to scopolamine in mice. Psychopharmacology (Berl) 1995;117:396-402.
200. Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 1993;72:394-7.
201. Muller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). Journal of Affective Disorders 2003;77(3):255-60.
202. Muller HK, Wegener G, Liebenberg N, Zarate CA Jr, Popoli M, Elfving B. Ketamine regulates the presynaptic release machinery in the hippocampus. J Psychiatr Res 2013;47:892-9.
203. Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG. A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord 2014;156:24-35.
204. Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. Journal of Affective Disorders 2014;156:24-35.
205. National Institute for Health and Clinical Excellence. Depression in adults: The treatment and management of depression in adults (CG90). http://publications.nice.org.uk/depression-in-adults-cg90 2009.
206. Papp M, Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 1994;263:1-7.
207. Papp M, Moryl E. Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol 1996;316:145-51.
208. Petty F, Sherman AD. Plasma GABA levels in psychiatric illness. J Affect Disord 1984;6:131-8.
209. Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, et al. Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression. Depression and Anxiety 2014;31:335-343.
210. Przegalinski E, Tatarczynska E, Deren-Wesolek A, Chojnacka-Wojcik E. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology 1997;36:31-7.
211. Quiroz JA, Gould TD, Manji HK. Molecular effects of lithium. Mol Interv 2004;4:259-72.
212. Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry 2005;162:1171-8.
213. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989;36:186-97.
214. Rendell JM, Shuttleworth C, Amit BH, Hawton K, Diamond P, McShane R, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database of Systematic Reviews in press.
215. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
216. Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007;12:331-59.
217. Salvadore G, Cornwell BR, Sambataro F, Latov D, Colon-Rosario V, Carver F, et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 2010;35:1415-22.
218. Smith DJ, Azzaro AJ, Zaldivar SB, Palmer S, Lee HS. Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology 1981;20:391-6.
219. Smith DJ, Bouchal RL, deSanctis CA, Monroe PJ, Amedro JB, Perrotti JM, et al. Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology 1987;26:1253-60.
220. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Archives General Psychiatry 1978;35(6):773-82.
221. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of Clinical Epidemiology 2000;53(11):1119-29.
222. Suh T, Gallo JJ. Symptom profiles of depression among general medical service users compared with specialty mental health service users. Psychological Medicine 1997;27(5):1051-63.
223. Thomas SP, Nandhra HS, Jarvaraman A. Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD). Journal of Mental Health 2010;19(2):168-175.
224. Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 2011;191:122-7.
225. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997;7:9-24.
226. Weber M, Motin L, Gaul S, Beker F, Fink RH, Adams DJ. Intravenous anaesthetics inhibit nicotinic acetylcholine receptor-mediated currents and Ca2+ transients in rat intracardiac ganglion neurons. Br J Pharmacol 2005;144:98-107.
227. World Health Organization (WHO). The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: WHO, 1992.
228. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). New York, NY: WHO, 2008.
229. World Health Organization (WHO). The global burden of disease: 2004 update. Geneva: WHO, 2008.
230. World Health Organization (WHO). Sixty-fifth World Health Assembly: daily notes on proceedings. Geneva: World Health Organization, 2012.
231. Zavodnick AD, Ali R. Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review. Psychiatric Quarterly 2012;83:371-383.
232. Zohar J, Nutt DJ, Kupfer DJ, Moller HJ, Yamawaki S, Spedding M, Stahl SM. A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmaco 2014;24(7):1005-14.